MedPath

Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

Not Applicable
Recruiting
Conditions
Tricuspid Valve Insufficiency
Tricuspid Regurgitation
Tricuspid Valve Disease
Interventions
Device: Edwards PASCAL System
Drug: Optimal Medical Therapy
Registration Number
NCT04097145
Lead Sponsor
Edwards Lifesciences
Brief Summary

To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Repair System in patients with symptomatic severe tricuspid regurgitation who have been determined to be at an intermediate or greater estimated risk of mortality with tricuspid valve surgery by the cardiac surgeon with concurrence by the local Heart Team

Detailed Description

A Prospective, multicenter, randomized, controlled pivotal trial to evaluate the safety and effectiveness of transcatheter tricuspid valve repair with the Edwards PASCAL Transcatheter Valve Repair System and optimal medical therapy (OMT) compared to OMT alone in patients with tricuspid regurgitation. Patients will be seen for follow-up visits at discharge, 30 days, 3 months, 6 months, and annually through 5 years.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
870
Inclusion Criteria
  • Eighteen (18) years of age or older
  • Despite medical therapy, per the local Heart Team, patient has signs of TR, symptoms from TR, or prior heart failure hospitalization from TR.
  • Severe or greater tricuspid regurgitation
  • New York Heart Association (NYHA) Class II-IVa or heart failure hospitalization in the prior 12 months
  • Patient is at an intermediate or greater estimated risk of mortality with tricuspid valve surgery as determined by the cardiac surgeon with concurrence by the local Heart Team
  • Patient is able and willing to give informed consent, follow protocol procedures, and comply with follow-up visit requirements
Exclusion Criteria
  • Tricuspid valve anatomy not evaluable by TTE or TEE

  • Tricuspid valve anatomy precludes proper device deployment and function

  • Patient with refractory heart failure requiring, advanced intervention (i.e. patient has or will need left ventricular assist device, or transplantation) (ACC/AHA Stage D heart failure)

  • Presence of trans-tricuspid pacemaker or defibrillator leads which meet one of the following:

    1. Would prevent proper TR reduction due to interaction of the lead with the leaflets
    2. Were implanted in the RV within the last 90 days prior to the point of enrollment
  • Primary non-degenerative tricuspid disease

  • Previous tricuspid valve repair or replacement that would interfere with placement of PASCAL

  • Clinically significant, untreated coronary artery disease requiring revascularization, unstable angina, evidence of acute coronary syndrome, recent myocardial infarction

  • Significant intra-cardiac mass, thrombus, or vegetation per echo core lab assessment

  • Deep vein thrombosis (DVT) or pulmonary embolism (PE) in the last 90 days

  • Recent Stroke

  • Active gastrointestinal (GI) bleeding

  • Presence of infiltrative cardiomyopathy or valvulopathy (including carcinoid, amyloidosis, sarcoidosis, hemochromatosis) or significant congenital heart disease, including but not limited to atrial septal defect, RV dysplasia, and arrhythmogenic RV

  • Need for emergent or urgent surgery for any reason, any planned cardiac surgery within the next 12 months (365 days), or any planned percutaneous cardiac procedure within the next 90 days

  • Any of the following cardiovascular procedures:

    1. Percutaneous coronary, intracardiac, or endovascular intervention within the last 30 days prior to the point of enrollment
    2. Carotid surgery within 30 days prior to the point of enrollment
    3. Direct current cardioversion within the last 30 days prior to the point of enrollment
    4. Leadless RV pacemaker implant within the last 30 days prior to the point of enrollment
    5. Cardiac surgery within 90 days prior to the point of enrollment
  • Severe aortic, mitral and/or pulmonic valve stenosis and/or regurgitation

  • Known history of untreated severe symptomatic carotid stenosis or asymptomatic carotid stenosis

  • Active endocarditis within the last 90 days or infection requiring antibiotic therapy within the last 14 days

  • Patient is oxygen-dependent or requires continuous home oxygen

  • Pregnant, breastfeeding, or planning pregnancy within the next 12 months (365 days)

  • Concurrent medical condition with a life expectancy of less than 12 months in the judgment of the Investigator

  • Patient is currently participating in another investigational biologic, drug, or device clinical study

  • Patient has other medical, social, or psychological conditions that preclude appropriate consent and follow-up, or the patient is under guardianship

  • Any patient considered to be vulnerable

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Edwards PASCAL System & OMTEdwards PASCAL SystemTranscatheter tricuspid valve repair with the Edwards PASCAL system in patients on optimal medical therapy (OMT) with tricuspid regurgitation
Optimal Medical Therapy (OMT)Optimal Medical TherapyOptimal medical therapy (OMT) alone in patients with tricuspid regurgitation
Single-Arm RegistryEdwards PASCAL SystemTranscatheter tricuspid valve repair with the Edwards PASCAL System in conjunction with optimal medical therapy (OMT) in patients with tricuspid regurgitation who are not eligible for randomization
Continued Access StudyEdwards PASCAL SystemTranscatheter tricuspid valve repair with the Edwards PASCAL system in patients on optimal medical therapy (OMT) with tricuspid regurgitation
Primary Outcome Measures
NameTimeMethod
Composite endpoint including all-cause mortality, RVAD implantation or heart transplant, tricuspid valve intervention, heart failure hospitalizations, and Quality of Life improvement (measured by KCCQ score)12 months

Comparison of number of participants with composite endpoint events between experimental and active comparator arms

Secondary Outcome Measures
NameTimeMethod
1 Grade Reduction in TR Severity6, 12 months

Total number of participants with at least 1 grade reduction in TR severity

Quality of Life (QOL) as Measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)3, 6, and 12 months

Change in KCCQ score from baseline

All Cause Mortality12 months, 24 months

Total number of deaths from any cause

Death and Heart Failure Hospitalizations12 months

Total number of deaths and hospital admissions due to heart failure

All-cause Hospitalization12 months

Total number of hospitalizations due to any cause

Right ventricular end-diastolic diameter (RVEDD mid)12 months

Change in right ventricular end-diastolic diameter (RVEDD mid)

Major Adverse Events (MAEs)30 days

Overall rate of Major Adverse Events (MAEs)

Reduction in TR gradeIntraprocedural post-implantation

Reduction in TR severity as assessed by TEE pre- and post-implantation

All-Cause Mortality12 months, annually through 5 years

Total number of deaths from any cause

Heart failure hospitalizations12 months, annually through 5 years

Total number of hospital admissions due to heart failure

Non-elective tricuspid valve re-intervenitions (percutaneous or surgical)12 months, annually through 5 years

Total number of non-elective tricuspid valve re-interventions

Durable RVAD implantation or heart transplant12 months, annually through 5 years

Total number of patients requiring RVAD impantantion or heart transplant

Need for paracentesis12 months, annually through 5 years

Total nunber of patients who required paracentesis

All cause mortality or the first heart failure hospitalization for patients with massive or torrential TR at baseline12, 24 months

Time to death or first heart failure hospitalization

Trial Locations

Locations (79)

Banner University Medical Center Phoenix

🇺🇸

Phoenix, Arizona, United States

Tucson Medical Center Healthcare

🇺🇸

Tucson, Arizona, United States

University of California, Irvine

🇺🇸

Irvine, California, United States

SCPMG - Kaiser San Diego

🇺🇸

La Jolla, California, United States

Cedars Sinai Medical Center

🇺🇸

Los Angeles, California, United States

UCLA Medical Center

🇺🇸

Los Angeles, California, United States

Kaiser Permanente San Francisco

🇺🇸

San Francisco, California, United States

University of California, San Francisco

🇺🇸

San Francisco, California, United States

Stanford University

🇺🇸

Stanford, California, United States

St. Joseph Hospital

🇺🇸

Denver, Colorado, United States

Medical Center of the Rockies

🇺🇸

Loveland, Colorado, United States

The Cardiac and Vascular Institute Research Foundation

🇺🇸

Gainesville, Florida, United States

Mount Sinai Medical Center

🇺🇸

Miami Beach, Florida, United States

NCH Healthcare System

🇺🇸

Naples, Florida, United States

Sarasota Memorial Health Care System

🇺🇸

Sarasota, Florida, United States

Tallahassee Research Institute

🇺🇸

Tallahassee, Florida, United States

Emory University Hospital Midtown / Emory University - St. Joseph's Hospital

🇺🇸

Atlanta, Georgia, United States

Piedmont Healthcare, Inc.

🇺🇸

Atlanta, Georgia, United States

Northwestern University

🇺🇸

Chicago, Illinois, United States

Ascension St. Vincent Heart Center Cardiovascular Research Institute

🇺🇸

Indianapolis, Indiana, United States

University of Iowa Hospitals & Clinics

🇺🇸

Iowa City, Iowa, United States

Ochsner Medical Center

🇺🇸

New Orleans, Louisiana, United States

Johns Hopkins

🇺🇸

Baltimore, Maryland, United States

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

University of Michigan

🇺🇸

Ann Arbor, Michigan, United States

Henry Ford Hospital

🇺🇸

Detroit, Michigan, United States

William Beaumont Hospital - Royal Oak

🇺🇸

Royal Oak, Michigan, United States

St. Mary's of Ascension Research

🇺🇸

Saginaw, Michigan, United States

Fairview Health Services

🇺🇸

Maplewood, Minnesota, United States

Mayo Clinic

🇺🇸

Rochester, Minnesota, United States

Saint Luke's Hospital of Kansas City

🇺🇸

Kansas City, Missouri, United States

Washington University School of Medicine

🇺🇸

Saint Louis, Missouri, United States

Providence St. Patrick Hospital

🇺🇸

Missoula, Montana, United States

Dartmouth-Hitchcock Medical Center

🇺🇸

Lebanon, New Hampshire, United States

Cooper Health Systems

🇺🇸

Camden, New Jersey, United States

Morristown Medical Center

🇺🇸

Morristown, New Jersey, United States

Rutgers Robert Wood Johnson Medical School

🇺🇸

New Brunswick, New Jersey, United States

Montefiore Medical Center / Arts Pavilion / Hutchinson Metro Center Clinic / Weiler Hospital / Moses Hospital

🇺🇸

Bronx, New York, United States

State University of New York at Buffalo

🇺🇸

Buffalo, New York, United States

Columbia University Irving Medical Center/NYPH

🇺🇸

New York, New York, United States

Weill Cornell Medicine

🇺🇸

New York, New York, United States

Lenox Hill Hospital, Northwell Health /Northshore University Hospital Manhasset

🇺🇸

New York, New York, United States

Rochester General Hospital

🇺🇸

Rochester, New York, United States

St. Francis Hospital

🇺🇸

Roslyn, New York, United States

University of North Carolina

🇺🇸

Chapel Hill, North Carolina, United States

Sanford Medical Center Fargo

🇺🇸

Fargo, North Dakota, United States

The Christ Hospital

🇺🇸

Cincinnati, Ohio, United States

TriHealth-Bethesda North Hospital

🇺🇸

Cincinnati, Ohio, United States

The Ohio State University

🇺🇸

Columbus, Ohio, United States

Integris Baptist Medical Center

🇺🇸

Oklahoma City, Oklahoma, United States

Oklahoma Cardiovascular Research Group

🇺🇸

Oklahoma City, Oklahoma, United States

Oklahoma Heart Institute at Hillcrest Medical Center

🇺🇸

Tulsa, Oklahoma, United States

Oregon Health & Science University

🇺🇸

Portland, Oregon, United States

Penn State Hershey

🇺🇸

Hershey, Pennsylvania, United States

Pennsylvania Presbyterian Medical Center / Hospital of the University of Pennsylvania

🇺🇸

Philadelphia, Pennsylvania, United States

Pinnacle Health Cardiovascular Institute/UPMC Pinnacle

🇺🇸

Wormleysburg, Pennsylvania, United States

Lankenau Heart Institute

🇺🇸

Wynnewood, Pennsylvania, United States

Medical University of South Carolina

🇺🇸

Charleston, South Carolina, United States

Erlanger Health System

🇺🇸

Chattanooga, Tennessee, United States

Vanderbilt University Medical Center

🇺🇸

Nashville, Tennessee, United States

HCA Houston Healthcare Medical Center

🇺🇸

Houston, Texas, United States

Baylor College of Medicine St. Luke's Medical Center

🇺🇸

Houston, Texas, United States

The University of Texas Health Science Center at Houston

🇺🇸

Houston, Texas, United States

UTHealth/Memorial Hermann Hospital

🇺🇸

Houston, Texas, United States

Baylor Scott & White - The Heart Hospital - Plano

🇺🇸

Plano, Texas, United States

Intermountain Medical Center

🇺🇸

Murray, Utah, United States

St. George Regional Hospital

🇺🇸

Saint George, Utah, United States

University of Virginia Health System

🇺🇸

Charlottesville, Virginia, United States

Virginia Commonwealth University

🇺🇸

Richmond, Virginia, United States

Carilion Medical Center

🇺🇸

Roanoke, Virginia, United States

Virginia Mason Medical Center

🇺🇸

Seattle, Washington, United States

Swedish Medical Center

🇺🇸

Seattle, Washington, United States

Medical College of Wisconsin

🇺🇸

Milwaukee, Wisconsin, United States

St. Paul's Hospital

🇨🇦

Vancouver, British Columbia, Canada

Hamilton Health Services

🇨🇦

Hamilton, Ontario, Canada

University of Ottawa Heart Institute

🇨🇦

Ottawa, Ontario, Canada

Sunnybrook Health Sciences Centre

🇨🇦

Toronto, Ontario, Canada

St. Michael's Hospital

🇨🇦

Toronto, Ontario, Canada

Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval

🇨🇦

Québec City, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath